Evidence map›Paper›PMID 42500826›Full record

ArticleBritish journal of haematology2026

Comparison of outcomes after DA-EPOCH-R or GMALL high-intensity therapy for front-line treatment of Burkitt lymphoma: A retrospective cohort.

Eduard Schulz, Florian Posch, Kristina Friedrich, Peter Neumeister, Katharina T Prochazka

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Eduard SchulzDivision of Haematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Florian PoschDivision of Haematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Kristina FriedrichDivision of Haematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Peter NeumeisterDivision of Haematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Katharina T ProchazkaDivision of Haematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this retrospective cohort of adult Burkitt lymphoma, DA-EPOCH-R showed no signal of inferior survival or relapse risk compared with GMALL-based high-intensity therapy. Outcomes were driven mainly by established prognostic factors, particularly age, advanced stage and Burkitt lymphoma International Prognostic Index.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBurkitt LymphomaCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposideFemaleHumansIfosfamideMethotrexatePrednisoneRetrospective StudiesRituximabTreatment OutcomeVincristineCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposideIfosfamideMethotrexatePrednisoneRituximabVincristineBurkitt lymphomaEPOCHGMALLnewly diagnosedoutcome

Identifiers

PMID42500826
PMCPMC13674111

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.